On April 4, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that members of Checkpoint’s management team will participate in the two-day Fortress Biotech ("Fortress") Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022 (Press release, Checkpoint Therapeutics, APR 4, 2022, View Source [SID1234611411]). The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Checkpoint will present a corporate overview and participate in a panel discussion on Wednesday, April 6, 2022 at 2:15 p.m. ET. Registration for the event is available here.

Following the meeting, the webcast will be available on the IR Calendar page under News & Events, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days following the meeting.